Follow Us:



CELLINK is the first bioink company in the world and the leading bioprinting technology provider. The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. CELLINK’s innovative and patent-pending bioink is a biomaterial innovation that enables human cells to grow and thrive as they would in the natural human body environment. Today, the company’s disruptive technology platform is being used to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments. The company has, within 12 months, commercialized products in more than 40 countries and sold to hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and the FDA. Follow us on our journey to change the world of medicine.


Academic users

World map
  • Distributor
Rest of the world30%
+40 Countries
+400 labs
+75 employees
Forbes: 30 Under 30 2018
Erik Gatenholm placed on Forbes 30 Under 30 2018!
Listing CELLINK on the NASDAQ Stock Exchange!
CELLINK IPO in November 2016
Hector Martinez featured at TEDx in Germany on February 3rd!
Anders Wall Entrepreneurship Award!
Erik Gatenholm wins the Anders Wall Entrepreneurship Award 2017
Founder's Alliance Entrepreneur of the Year
Erik Gatenholm wins Entrepreneur of the Year.
The Medicine Maker Power List 2018
Erik Gatenholm Placed On the Medicine Maker Top 100
Nordic Health Startup of the Year!
Nordic Health Startup of the Year
Arvid Carlsson Entrepreneurship Award!
CELLINK wins the Arvid Carlsson Entrepreneurship Award 2017